Literature DB >> 22001547

Functional characterization and expression analysis of novel alternative splicing isoforms of Olr1 gene during mouse embryogenesis.

Lucia Vecchione1, Laura Diano, Luisa Campagnolo, Lucia Rocchi, Fabrizio Ferrè, Jawahar L Mehta, Giuseppe Novelli, Francesca Amati.   

Abstract

LOX-1 (Lectin-like oxidized low-density lipoprotein receptor-1) is the primary endothelial receptor of oxidized LDL (oxLDL). Both in vitro and in vivo experiments have shown this protein to be important in the initiation of atherosclerosis and to be up-regulated by pro-atherogenic factors. Recently, it has been demonstrated that Olr1, the gene encoding Lox-1, is important for tumor growth and for maintaining the transformed state in different cancer cell lines, suggesting that it acts in a molecular pathway connecting cancer and atherosclerosis. Both diseases in humans are characterized by uncontrolled regulation of cellular growth and differentiation. We present evidence that Olr1 is expressed during mouse embryogenesis in developmental stages (from 7.5 to 9.5 dpc) in which cardiogenesis occurs. In addition, we identify two novel Olr1 isoform (hereafter referred to as D3D5Olr1 and D2D5Olr1) whose spatio-temporal expression pattern overlaps with Olr1 in vivo. In vitro, D3D5Olr1 localizes to the cell surface membrane as Olr1, in contrast with D2D5Olr1; these data suggest that D2D5Olr1 isoform translates a receptor that does not reach the plasma membrane. Accordingly, in silico transmembrane protein topology prediction analyses, show that D2D5Olr1 does not contain any transmembrane region. Finally, both isoforms can activate the same genetic pathways underlying Olr1 expression, such as, hypoxia and inflammation, even if with a different efficiency. All these data suggest a new functional involvement of Olr1, and probably of its spliceforms, in murine cardiogenesis and angiogenesis. Copyright Â
© 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001547     DOI: 10.1016/j.gene.2011.09.030

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  2 in total

Review 1.  LOX-1 and Its Splice Variants: A New Challenge for Atherosclerosis and Cancer-Targeted Therapies.

Authors:  Barbara Rizzacasa; Elena Morini; Sabina Pucci; Michela Murdocca; Giuseppe Novelli; Francesca Amati
Journal:  Int J Mol Sci       Date:  2017-01-29       Impact factor: 5.923

2.  Pro-oncogenic action of LOX-1 and its splice variant LOX-1Δ4 in breast cancer phenotypes.

Authors:  Sabina Pucci; Chiara Polidoro; Chiara Greggi; Francesca Amati; Elena Morini; Michela Murdocca; Michela Biancolella; Augusto Orlandi; Federica Sangiuolo; Giuseppe Novelli
Journal:  Cell Death Dis       Date:  2019-01-18       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.